A:

Biotech giant Amgen Inc (AMGN) bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales. Below is an overview of its main rivals.

Product Rivals

Any pharmaceutical or biotech firm is technically a rival to Amgen, though there is a smaller subset of rivals that sell similar drugs to Amgen. For instance, Johnson & Johnson (JNJ) sells Procrit, which is a competitor to Aranesp and Amgen’s stable of anemia treatments. Teva Pharmaceutical (TEVA) also sells an increasing array of biosimilar drugs to Aranesp  Amgen’s Enbrel helps treat arthritis, which competes with AbbVie’s (ABBV) popular Humira drug. Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.      

Biotech Competition

In general, Amgen competes with other large biotech firms. Biogen Idec (BIIB) sells a number of drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of drugs to treat hemophilia. Celgene sells drugs that help treat cancer and immune-inflammatory diseases. Gilead Sciences (GILD) offers a number of drugs that help patients suffering from HIV and recently released Solvadi, which has had great success in helping patients with hepatitis C infections.

The Bottom Line

A number of firms continue to muscle into Amgen’s core businesses of treating anemia, arthritis, and myeloma. Generic versions will also continue to be introduced as Amgen’s drug patents expire over time. Most investment bankers and analysts, however, still project Amgen will remain profitable over time. 

At the time of writing, Ryan C. Fuhrmann is long shares of Amgen and Gilead but did not own shares in any of the other companies mentioned in this article.

RELATED FAQS
  1. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  2. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  3. Who are Pfizer's (PFE) main competitors?

    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ... Read Answer >>
  4. What metrics are often used to evaluate companies in the drugs sector?

    Learn about some of the equity evaluation metrics that are most frequently used for examining companies in the pharmaceutical ... Read Answer >>
  5. What are some common traits of undervalued stocks?

    There are a few basic factors found in companies that are worth more than their current stock price. Read Answer >>
  6. What are the differences between period costs and product costs?

    Find out why GAAP separates all company expenses into either period or production costs and how this impacts the way expenses ... Read Answer >>
Related Articles
  1. Investing

    Amgen Earnings Preview: 5 Questions to Ask (AMGN)

    In the biotechnology sector, few companies are more synonymous with innovation than Amgen (NASDAQ: AMGN). Throughout the 1980s and 1990s, Amgen was a model drug development company, rewarding ...
  2. Investing

    Amgen Tops Q3 Profit Projections (AMGN)

    Aided by the decrease of expenses such as late state clinical trials, Amgen reported positive third-quarter earnings.
  3. Insights

    Amgen’s Kyprolis Fails in Trial (AMGN)

    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  4. Investing

    How Amgen Makes Billions On Just A Few Drugs

    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the $120B company.
  5. Investing

    Amgen Q4 Earnings Beat Street Forecasts

    Amgen's 4Q earnings and revenue beat analyst projections.
  6. Investing

    Biotech Stocks Are Suddenly a Bargain

    The huge drop in biotech stocks has turned many into bargains, including Amgen, Biogen and others.
  7. Investing

    3 Biotech Blue-Chip Companies to Keep an Eye On (AMGN, BIIB)

    Discover three blue-chip biotech stocks you should keep your eye on in 2016. Despite recent struggles in the industry, these stocks are poised for a comeback.
  8. Investing

    Amgen's Dividend Could Double in 5 Years (AMGN)

    Amgen's (NASDAQ: AMGN) dividend yield of 1.9% may not look very enticing to investors looking for income today. But a close look at Amgen stock reveals that where the biotechnology company lacks ...
  9. Insights

    Long Wait for Biosimilar Amjevita (AMGN)

    While Amgen’s Humira biosimilar called Amjevita has been approved by the FDA, it will be a very long wait for real commercial benefits.
  10. Insights

    Amgen Targeting Biosimilars (AMGN)

    Amid emerging biosimilar challenges, Amgen is taking the legal route to thwart and delay competition, in addition to pursuing its own biosimilar programs.
RELATED TERMS
  1. New Drug

    A new medication or therapy that has not been used before in ...
  2. Orange Book

    The Orange Book is a list of drugs that the U.S. Food and Drug ...
  3. New Drug Application (NDA)

    The New Drug Application (NDA) is the formal final step taken ...
  4. Food And Drug Administration - FDA

    The Food and Drug Administration is a government agency that ...
  5. Bioequivalence

    Bioequivalence represents the similarity between two drugs that ...
  6. Side Effect

    Undesirable symptoms caused by taking a drug or undergoing a ...
Hot Definitions
  1. Bond

    A bond is a fixed income investment in which an investor loans money to an entity (corporate or governmental) that borrows ...
  2. Compound Annual Growth Rate - CAGR

    The Compound Annual Growth Rate (CAGR) is the mean annual growth rate of an investment over a specified period of time longer ...
  3. Net Present Value - NPV

    Net Present Value (NPV) is the difference between the present value of cash inflows and the present value of cash outflows ...
  4. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing a company that measures its current share price relative ...
  5. Internal Rate of Return - IRR

    Internal Rate of Return (IRR) is a metric used in capital budgeting to estimate the profitability of potential investments.
  6. Limit Order

    An order placed with a brokerage to buy or sell a set number of shares at a specified price or better.
Trading Center